Optical Biopsy in Gynecological Surgery
Eligible age
18+ yrs
Accepts
Women
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Optical biopsy is a new technology that generates a real-time, cell-based, high-resolution view and analysis of tissues. Observation is instantaneous and non-invasive. This allows reliable and fast diagnosis which facilitates decision making as well as patient management. The investigator have already conducted a feasibility study on the use of this new technology to evaluate ovarian and tubal pre-cancerous lesions in laparoscopy. In this new study, he wants to continue investigations, expand its use to other gynecological pathologies, and demonstrate the benefit of such a non-invasive technology in gynecology on the one hand in the diagnosis of lesions but also to appreciate the margins as accurately as possible surgical excision of tumors and / or endometriosis lesions. The investigator have set up a prospective monocentric descriptive study. The hypothesis is that optical biopsy by Cellvizio® allows to observe in real time microscopically tissues and to characterize them in the field of gynecological surgery
Sponsor: Hospices Civils de Lyon
You may qualify if…
- ✓ Women aged 18 years or more
- ✓ Informed and signed consent
- ✓ Planned surgery under laparoscopy and included in the list below:
- ✓ unilateral or bilateral salpingectomy
- ✓ hysterectomy
- ✓ ovariectomy
- ✓ surgery of endometriosis
- ✓ surgery for cancer of the cervix, endometrium, ovaries
You may not qualify if…
- ✕ Interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc.
- ✕ Pregnancy or desire of pregnancy during the study period, breastfeeding
- ✕ Hypersensitivity to Fluorescein or any of its excipients
- ✕ History of life-threatening reaction during angiography
- ✕ Known allergic reactions and hypersensitivity
- ✕ Severe asthma, heart and / or lung disease, diabetes
- ✕ Person on beta-blocker treatment
- ✕ Inability to understand information provided
Source: ClinicalTrials.gov · NCT04154683 · last updated 2026-01-15